Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CGON vs XNCR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
XNCR Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 5–5 Matrix Metrics)
XNCR Overall Winner
6-Pillar Tally: CGON 1 – 5 XNCR
Matrix Metrics: CGON 5 – 5 XNCR
As of Nov 16, 2026, Xencor, Inc. (XNCR) is the stronger overall head-to-head candidate over CG Oncology, Inc. (CGON) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CGON carries a Unified Composite Score of 45.0/100 (HOLD) at $84.94 (N/M Forward P/E, -4293.5% operating margin), whereas XNCR carries 29.6/100 (SELL) at $35.61 (68.0x Forward P/E, -72.7% operating margin).
- Composite vs. Pillar Nuance: While CGON currently prints a higher short-term Unified Composite Score (45.0/100 HOLD vs. XNCR 29.6/100 SELL), XNCR captures the overall institutional head-to-head verdict (5–5 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-72.7% vs. -4293.5% operating margin) and revenue trajectory (+454.9% vs. -3.7% YoY).
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About CGON vs XNCR
CGON
CG Oncology, Inc. Common stock
$84.94
+14.16% 1D
Market Cap
$6.3B
TTM Revenue
$6.2M
Forward P/E
N/M
Beta / 30D Vol
0.77β · 86% Vol
Unified Composite Score
45.0
HOLD
Tech 15.0
Fund 44.0
Flow 69.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
XNCR
Head-to-Head Winner
Xencor, Inc.
$35.61
-3.99% 1D
Market Cap
$2.9B
TTM Revenue
$200M
Forward P/E
68.0x
Beta / 30D Vol
1.21β · 87% Vol
Unified Composite Score
29.6
SELL
Tech 50.0
Fund 32.0
Flow 66.0
Mom 40.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (CGON 1 – 5 XNCR)
1. Valuation Multiples
XNCR
Forward P/E
N/M
68.0x
Trailing P/E
N/M
68.0x
PEG Ratio
N/M
N/M
EV / Revenue
N/M
14.8x
2. Growth & Scale
XNCR
Revenue Growth (YoY)
-3.7%
+454.9%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$6.2M
$200M
Market Cap
$6.3B
$2.9B
3. Profitability & Quality
XNCR
Gross Margin
N/A
-42.5%
Operating Margin
-4293.5%
-72.7%
Net Profit Margin
0.0%
-58.8%
Return on Equity (ROE)
-28.3%
-19.9%
4. Balance Sheet & Cash Flow
XNCR
Cash Generation (TTM)
-$189M
-$176M
Cash Flow Margin
N/A
-88.0%
Net Cash / Leverage
$19M Net Cash
$101M Net Debt (0.29x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
CGON
Options Structure Phase
CONSOLIDATION
BREAKOUT
Current IV / %ile
238.6% (85th %ile)
79.0% (10th %ile)
Put/Call OI Skew
0.35x (Call-Skewed)
N/A
OBV Trend / Tech Phase
ACCUMULATION · Neutral
ACCUMULATION · Markup
6. R&D & Supply-Chain Moat
XNCR
OpEx & R&D Intensity
N/A
30.2% of Rev ($61M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: CGON (5) vs XNCR (5)| Institutional Metric | CGON | XNCR | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $6.3B | $2.9B | CGON | |
| Trailing P/E Ratio | N/M | 68.0x | XNCR | |
| Forward P/E Ratio | N/M | 68.0x | XNCR | |
| Revenue Growth (YoY) | -3.7% | +454.9% | XNCR | |
| Operating Margin (TTM) | -4293.5% | -72.7% | XNCR | |
| Net Profit Margin | 0.0% | -58.8% | CGON | |
| Return on Equity (ROE) | -28.3% | -19.9% | XNCR | |
| 52-Week Range Position | 84% ($37–$94) | 84% ($10–$41) | CGON | |
| Beta / 30D Volatility | 0.77β · 86% Vol | 1.21β · 87% Vol | CGON | |
| Unified Institutional Score | 45.0 / 100 (HOLD) | 29.6 / 100 (SELL) | CGON | |
| Trailing 12M Revenue (USD) | $6.2M | $200M | Scale | |
| Gross Profit Margin (TTM) | N/A | -42.5% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · 14.8x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$189M ($19M Net Cash) | -$176M ($101M Net Debt (0.29x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
XNCR +13.93 pp
3M Horizon
XNCR +28.81 pp
6M Horizon
XNCR +187.0 pp
1Y Horizon
XNCR +29.61 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CGON Revenue | XNCR Revenue | CGON Op. Margin | XNCR Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | N/A | $40M | N/A | -195.5% | XNCR |
| FY2019 | N/A | $160M | N/A | 8.8% | XNCR |
| FY2020 | N/A | $120M | N/A | -62.6% | XNCR |
| FY2021 | N/A | $280M | N/A | 15.9% | XNCR |
| FY2022 | N/A | $160M | N/A | -50.1% | XNCR |
| FY2023 | $0M | $170M | -27180.9% | -75.8% | XNCR |
| FY2024 | $0M | $110M | -10067.3% | -161.5% | XNCR |
| FY2025 | $0M | $130M | -4722.1% | -141.4% | XNCR |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
CGON
CONSOLIDATION
Current IV
238.6%
IV Percentile
85th %ile
Put/Call OI Skew
0.35x (Call-Skewed)
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact CGON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
XNCR
BREAKOUT
Current IV
79.0%
IV Percentile
10th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
ACCUMULATION
Exact XNCR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
CGON Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
XNCR Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
30.2% of Rev ($61M)
90D Engineering Disclosures
0 Published
Investor FAQ CGON vs XNCR Key Questions & Quantitative Answers
As of Nov 16, 2026, Xencor, Inc. (XNCR) is the stronger overall head-to-head candidate over CG Oncology, Inc. (CGON) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CGON carries a Unified Composite Score of 45.0/100 (HOLD) at $84.94 (N/M Forward P/E, -4293.5% operating margin), whereas XNCR carries 29.6/100 (SELL) at $35.61 (68.0x Forward P/E, -72.7% operating margin). Composite vs. Pillar Nuance: While CGON currently prints a higher short-term Unified Composite Score (45.0/100 HOLD vs. XNCR 29.6/100 SELL), XNCR captures the overall institutional head-to-head verdict (5–5 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-72.7% vs. -4293.5% operating margin) and revenue trajectory (+454.9% vs. -3.7% YoY).
XNCR leads the Growth & Scale pillar: CGON posts -3.7% YoY revenue growth and +0.0% YoY earnings growth on $6.2M TTM revenue (N/A gross margin, -4293.5% operating margin), compared with XNCR at +454.9% YoY revenue growth and +0.0% YoY earnings growth on $200M TTM revenue (-42.5% gross margin, -72.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CGON cumulative revenue shifted N/A while XNCR shifted +225.0%. In operating R&D and SG&A reinvestment, CGON deploys N/A (0 90-day corporate R&D disclosures) versus 30.2% of Rev ($61M) (0 disclosures) for XNCR.
XNCR screens cheaper on headline valuation multiples. CGON trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas XNCR trades at 68.0x Forward P/E, 68.0x Trailing P/E, N/M PEG, and 14.8x EV/Revenue (-88.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CGON (-28.3% ROE) versus XNCR (-19.9% ROE) capital efficiency.
In options market volatility and institutional positioning, CGON carries 238.6% implied volatility (85th %ile, Extreme (>80th %ile)), a 0.35x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.77β · 86% Vol realized risk). By comparison, XNCR carries 79.0% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.21β · 87% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
XNCR vs CGON · Reverse Pair
CGON vs AVBP
· Sector Peer
CGON vs SYRE
· Sector Peer
CGON vs MLYS
· Sector Peer
XNCR vs ENTA
· Sector Peer
XNCR vs ANAB
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem